Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Bulent Karabulut"'
Autor:
Erman Mustafa, Biswas Bivas, Danchaivijitr Pongwut, Chen Lingwu, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandra Chikatapu, Sara Ingles, Khemaies Slimane, Ravindran Kanesvaran
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking. Methods PARACHUTE is a phase IV, prospective, non-
Externí odkaz:
https://doaj.org/article/15fd4b63d38742ba964f1220eda09e72
Autor:
Suayib Yalcin, Faysal Dane, Berna Oksuzoglu, Nuriye Yildirim Ozdemir, Abdurrahman Isikdogan, Metin Ozkan, Guzin Gonullu Demirag, Hasan Senol Coskun, Bulent Karabulut, Turkkan Evrensel, Mehmet Ali Ustaoglu, Feyyaz Ozdemir, Hande Turna, Tugba Yavuzsen, Faruk Aykan, Alper Sevinc, Hakan Akbulut, Deniz Yuce, Mutlu Hayran, Saadettin Kilickap
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in a
Externí odkaz:
https://doaj.org/article/1ae3c043ebb54a6c82250c0cb4ea7be9
Autor:
Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandrasekhar Chikatapu, Sara Ingles, Khemaies Slimane, Ravindran Kanesvaran
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/c4088abcfc2b4a2295bba6b69afcf827
Autor:
Gulcan Bulut, Merve Guner Oytun, Elvina Almuradova, Mustafa Harman, Ruchan Uslu, Bulent Karabulut
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Background The aim of the study is to reveal the contribution of complete response (CR) to treatment to overall survival (OS) in patients with unresectable metastatic colorectal cancer. In addition, to evaluate progression-free survival (PFS) in pati
Externí odkaz:
https://doaj.org/article/be133167b4e84d62ad4d93c155ed2563
Autor:
Burcu Cakar, Ugur Muslu, Emir Bozkurt, Harika Atmaca, Burcak Karaca, Bulent Karabulut, Ruchan Uslu
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 2, Pp 65-69 (2018)
Aim: Glioblastoma multiforme (GBM) is the most common glial tumor. Angiogenesis which provides nutrient and oxygen support to proliferating cells play an essential role in GBM development, proliferation and metastasis. The development of antiangiogen
Externí odkaz:
https://doaj.org/article/453d0ca370f7457b99d6aedb4578bffa
Autor:
Erhan Akgun, Serdar Ozkok, Mevlut Tekin, Tayfun Yoldas, Cemil Caliskan, Timur Kose, Bulent Karabulut, Murat Sezak, Nevra Elmas, Omer Ozutemiz
Publikováno v:
World Journal of Surgical Oncology, Vol 15, Iss 1, Pp 1-10 (2017)
Abstract Background There are only two prospective, randomized studies comparing preoperative long-term chemoradiotherapy and postoperative chemoradiotherapy in locally advanced rectal cancer (LARC); however, conflicting results in terms of locoregio
Externí odkaz:
https://doaj.org/article/c1423613f93f4f42b8f38c8420d6bb42
Autor:
Bülent Karabulut, Burcu Çakar
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 630-639 (2024)
Introduction: Although long-term survival in patients with metastatic colorectal cancer (mCRC) is limited, treatments for third-line and later treatment are now recommended. We describe a patient who achieved long-term survival when they received thi
Externí odkaz:
https://doaj.org/article/cab300c40ec24dde8134b77559ec4501
Autor:
Tarek Hashem, Chandrasekhar Chikatapu, Bivas Biswas, Yoke Fui Wong, K. Slimane, Ravindran Kanesvaran, Sara Ingles, Mustafa Erman, Chun Sen Lim, Lingwu Chen, Hsiao-Jen Chung, Bulent Karabulut, P. Danchaivijitr
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking. Methods PARACHUTE is a phase IV, prospective, non-intervent
Autor:
Faysal Dane, Bulent Karabulut, Senem Karabulut, Nilufer Avci, Hasan Şenol Coşkun, Levent Korkmaz, Devrim Cabuk, Nazim Serdar Turhal, Mustafa Karaagac, Nuri Faruk Aykan, Hatice Doruk, Mehmet Artac
Publikováno v:
Surgical Oncology. 27:485-489
Purpose We aimed to investigate the prognostic effect of primary tumor resection (PTR) prior to bevacizumab-based treatments in unresectable metastatic colorectal cancer (mCRC). Methods We retrospectively collected 341 mCRC cases with unresectable me
Autor:
Cemil Caliskan, Mustafa Harman, Serdar Özkök, Osman Bozbıyık, Timur Köse, Ömer Özütemiz, Bulent Karabulut, Murat Sezak, Erhan Akgün, Tayfun Yoldas
Publikováno v:
British Journal of Surgery. 105:1417-1425
BackgroundThe optimal timing of surgery following preoperative chemoradiotherapy (CRT) is controversial. This trial aimed to compare pathological complete response (pCR) rates obtained after an interval of 8 weeks or less versus more than 8 weeks.Met